ArticleBioinformatics (Oxford, England)2024
AutoPeptideML: a study on how to build more trustworthy peptide bioactivity predictors.
Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Next-generation probiotics: an outlook into current applications and future developments.Nature reviews. Microbiology · 2026Review
- NeuroPred-GMC: a dual-branch deep learning architecture for neuropeptide prediction based on gated dilated convolutional network and multi-scale convolutional network.Journal of computer-aided molecular design · 2026Article
- Contemporary data-driven innovations in peptide-based therapeutic design.Briefings in bioinformatics · 2026Review
- Molecular fingerprints are strong models for peptide function prediction.Bioinformatics (Oxford, England) · 2026Article
- SGAC: a graph neural network framework for imbalanced and structure-aware AMP classification.Briefings in bioinformatics · 2026Article
- Architectural good practices for reproducible benchmarking in protein machine learning.Frontiers in bioinformatics · 2026Article
- Recent advances in multimodal foundation model-enabled peptide screening and optimization for smart biomaterials and functional tissue engineering.Frontiers in bioengineering and biotechnology · 2026Review
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- How to build machine learning models able to extrapolate from standard to modified peptides.Journal of cheminformatics · 2025Article
- Article
- AI Methods for Antimicrobial Peptides: Progress and Challenges.Microbial biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
motivationAutomated machine learning (AutoML) solutions can bridge the gap between new computational advances and their real-world applications by enabling experimental scientists to build their own custom models. We examine different steps in the development life-cycle of peptide bioactivity binary predictors and identify key steps where automation cannot only result in a more accessible method, but also more robust and interpretable evaluation leading to more trustworthy models.
resultsWe present a new automated method for drawing negative peptides that achieves better balance between specificity and generalization than current alternatives. We study the effect of homology-based partitioning for generating the training and testing data subsets and demonstrate that model performance is overestimated when no such homology correction is used, which indicates that prior studies may have overestimated their performance when applied to new peptide sequences. We also conduct a systematic analysis of different protein language models as peptide representation methods and find that they can serve as better descriptors than a naive alternative, but that there is no significant difference across models with different sizes or algorithms. Finally, we demonstrate that an ensemble of optimized traditional machine learning algorithms can compete with more complex neural network models, while being more computationally efficient. We integrate these findings into AutoPeptideML, an easy-to-use AutoML tool to allow researchers without a computational background to build new predictive models for peptide bioactivity in a matter of minutes. AVAILABILITY AND IMPLEMENTATION: Source code, documentation, and data are available at https://github.com/IBM/AutoPeptideML and a dedicated web-server at http://peptide.ucd.ie/AutoPeptideML. A static version of the software to ensure the reproduction of the results is available at https://zenodo.org/records/13363975.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.